Disulfiram presents a promising, mechanistically grounded candidate for the treatment of endometriosis. Its unique ability to simultaneously modulate inflammation, oxidative stress, pyroptosis, and angiogenesis aligns closely with the multifactorial pathology of EMS. This review provides a strong rationale for future pre-clinical and clinical investigations to formally evaluate the efficacy and safety of DSF repurposing for this challenging disease.
Wang et al. (Thu,) studied this question.